Prostatic Intraepithelial Neoplasia

Sandalwood oil has been used worldwide for centuries. Now, a study is the first to demonstrate in vivo the chemo-preventive properties of a by-product of the oil in a mouse model. Results show administering alpha-santalol reduced visible prostate tumors, protected the normal tissue, and delayed progression from a precancerous condition to a high-grade form of cancer. These findings are significant because mortality in prostate cancer patients is mainly attributable to advanced stages of the disease. Extracted from the core of sandalwood trees (santalum album tree), sandalwood oil has been used for many centuries by several cultures throughout the world for perfume, soaps, incense and candles. With its earthy sweet scent, this essential oil also is used in the food industry and topically in various cosmetic preparations. Importantly, this natural oil is known for its health benefits and medicinal applications from antibacterial to anticancer because of its phytochemical constituents. In addition to containing esters, free acids, aldehydes, ketones and santenone, sandalwood oil primarily (90 percent or more) constitutes santalol -- equal amounts of two compounds, alpha and beta-santalol. Now, researchers from Florida Atlantic University's Schmidt College of Medicine and collaborators are the first to demonstrate in vivo the chemo-preventive properties of alpha-santalol against prostate cancer development using a transgenic mouse model. Results of the study, published in the journal Phytomedicine Plus, showed that administration of alpha-santalol decreased the incidence of prostate tumors by decreasing cell proliferation and inducing apoptosis, without causing weight loss or any noticeable side effects. Apoptosis, or programmed cell death, is a method the body uses to get rid of unneeded or abnormal cells such as cancer cells. Findings revealed that the area occupied by normal tissue in alpha-santalol-treated mice was 53 percent compared to 12 percent in control mice. This suggests that administering alpha-santalol protected the normal tissue and delayed progression from prostatic intraepithelial neoplasia, a precancerous condition, to poorly differentiated carcinoma, a high-grade form of cancer where cancer cells and tissue look very abnormal. These results are significant because mortality in prostate cancer patients is mainly attributable to advanced stages of the disease. In prior studies, the researchers demonstrated the efficacy of alpha-santalol in suppressing growth and inducing apoptotic cell death in cultured human prostate cancer cells. Based on these observations, they selected a genetically engineered mouse model that resembles many features similar to human prostate cancer, eliciting different lesion grades and cancer progression. "Although our cellular studies provided important mechanistic insights, relevant in vivo models are vital for developing novel chemo-preventive agents for clinical use and to determine if alpha-santalol offers protection against prostate cancer development," said Ajay Bommareddy, Ph.D., senior author and an associate professor of pharmacology in the Department of Biomedical Science, FAU Schmidt College of Medicine. "Prior to this new study, alpha-santalol's in vivo efficacy against prostate cancer development had not yet been established." Additional findings of the current study showed alpha-santalol reduced the incidence of visible prostate tumors compared to control-treated mice. Only 11 percent in the treated group developed prostate tumors whereas more than half in the control group developed the tumors. The differences in urogenital and prostate weights were statistically significantly different in alpha-santalol-treated mice compared with controls. The average wet weight of urogenital tract in alpha-santalol treated mice was about 74.28 percent lower compared with control mice. Similarly, the average wet weight of the prostate gland was lower by 52.9 percent compared with control mice. Prostate cancer is the second leading cause of cancer death in men in the United States. An estimated 288,300 new cases were diagnosed in American men last year with about 34,700 estimated deaths. Current treatment methods for prostate cancer include androgen ablation, chemotherapy, radiotherapy and radical prostatectomy, but are ineffective against advanced prostate cancers. Early detection and local therapy have resulted in improved outcomes but has been challenging with the management of advanced stages. "Identifying agents that have the ability to selectively target cancerous cells and delay onset and progression of prostate cancer is greatly needed," said Bommareddy. "Additional studies are essential to systemically explore the feasibility of alpha-santalol as a promising chemo-preventive and anti-tumor agent against human prostate cancer development and to elucidate the mechanisms surrounding the role of pro-apoptotic and antiapoptotic proteins." Study co-authors are John Oberlin Jr., PharmD; Kaitlyn Blankenhorn, PharmD; Sarah Hughes, PharmD; Erica Mabry, PharmD; Aaron Knopp, PharmD; Adam L. VanWert, PharmD, Ph.D., all with the Wilkes University Nesbitt School of Pharmacy; Chandradhar Dwivedi, Ph.D., South Dakota State University; Isaiah Pinkerton, a graduate of Wilkes University; and Linda Gutierrez, M.D., Wilkes University.

DUBLIN--( BUSINESS WIRE )--The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028. As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical. The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market. The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs. The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages. The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028. This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report. The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies Profiles of leading market participants Key Attributes: Report Attribute Details No. of Pages 157 Forecast Period 2023 - 2028 Estimated Market Value (USD) in 2023 $37.9 Billion Forecasted Market Value (USD) by 2028 $56.4 Billion Compound Annual Growth Rate 8.3% Regions Covered Global Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Prostate Cancer Biology of Prostate Cancer Symptoms Screening Diagnosis Localized Prostate Cancer Metastatic Prostate Cancer Watchful Waiting or Active Surveillance Treatment Chapter 4 Market Dynamics Market Drivers Increasing Prevalence of Prostate Cancer Active Surveillance and Screening Personalized Care Approvals for Metastatic Castration-Resistant Prostate Cancer Collaborations and Licensing Agreements Market Challenges Loss of Exclusivity and Genericization Shortage of Care Providers and Other Resources Market Opportunities Chapter 5 Screening and Diagnosis Market by Test Type Biomarker Tests PSA Tests Limitations of PSA Tests Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings Digital Rectal Exam Limitations of DREs Prostate Biopsy Grade (Gleason Score) of Prostate Cancer Prostatic Intraepithelial Neoplasia Atypical Small Acinar Proliferation Proliferative Inflammatory Atrophy Intraductal Carcinoma of the Prostate Limitations of Prostate Biopsies Imaging Technologies for Prostate Cancer Market for Prostate Cancer Screening/Diagnosis, by Test Type Biomarker Tests DREs Prostate Biopsies Chapter 6 Pharmaceuticals Market by Drug Type Hormone Therapy Androgen Deprivation Therapy Antiandrogen Therapies Hormone Therapy Uses in Prostate Cancer Treatment Targeted Therapy PARP Inhibitors Radioligand Therapies Small Molecule Targeted Agents Monoclonal Antibodies Chemotherapy Immunotherapy Market Revenue, by Drug Type Hormone Therapy Targeted Therapy Immunotherapy Chemotherapy Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type Active Surveillance Radical Prostatectomy Robotic Prostatectomy Open Radical Prostatectomy Laparoscopic Prostatectomy Radical Prostatectomy Market Revenue Radiation Therapy External Beam Radiation Therapy Brachytherapy Combined Radiation Therapy Radiation Therapy Device Market Revenue Chapter 8 Market Breakdown by Region Chapter 9 Emerging Technologies and Developments Liquid Biopsy Multiparametric MRI Homologous Recombination Repair Gene Mutation Advanced Radiotherapy Techniques AI and Machine Learning Chapter 10 Pipeline Analysis Chapter 11 Competitive Intelligence Screening and Diagnosis Market Market for Radiation Therapy Devices Pharmaceuticals Market Chapter 12 Company Profiles Abbott Accuray Astellas Pharma Astrazeneca Bayer Danaher Corp. Dendreon Pharmaceuticals Elekta F. Hoffmann-La Roche Johnson & Johnson Services Pfizer Sanofi Siemens Healthineers For more information about this report visit https://www.researchandmarkets.com/r/wra8q3 About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

DUBLIN, Feb. 9, 2024 /PRNewswire/ -- The "Prevention and Treatment of Prostate Cancer: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for prostate cancer care reached $35.3 billion in 2022. This market is expected to reach $56.4 billion by the end of 2028, growing at a CAGR of 8.3% from 2023 through 2028. As the second most diagnosed male cancer in the world, prostate cancer affects roughly 1.4 million people and kills more than 370,000 men each year, which represents about 4% of all cancer deaths worldwide. This cancer ranges from being a non-aggressive, slow-growing type that can do without treatment to an aggressive, fast-growing disease that needs intervention and timely treatment. Hence, early detection/screening, diagnosis and staging of prostate cancer are critical. The global market for prostate cancer screening and detection is projected to grow at a CAGR of 5.8% to reach $19.8 billion by the end of 2028. It is estimated that over 60% of age-eligible men remain unscreened for prostate cancer. A large, underserved population of unscreened and inadequately screened patients represents a significant opportunity for non-invasive biomarker tests in the prostate cancer screening market. The global market for prostate cancer pharmaceuticals was valued at $16.0 billion in 2022 and is expected to reach $29.6 billion by the end of 2028, at a CAGR of 11.0% during the forecast period. Continued incidence of prostate cancer, the world's growing elderly population, and increasing therapeutic innovations are key driving factors in the market for prostate cancer drugs. The direct cost for radical prostatectomy was estimated at $3.6 billion in 2022. This cost is expected to rise to $4.8 billion by the end of 2028. The growing popularity of robot-assisted laparoscopic prostatectomy (RALP) is expected to impact the overall radical prostatectomy market. Improved screening programs will result in an increase in radical prostatectomies, as this procedure is preferred in early detection stages. The radiotherapy device market is expected to grow as the incidence of prostate cancer worldwide continues to increase and better and more accurate imaging technologies combined with precise treatment strategies are developed. This market is expected to reach $2.2 billion by the end of 2028. This research study analyzes the state of prostate cancer care, including screening, detection and treatment, offers revenue forecasts, assesses future trends, and provides recommendations for the success of market participants. The scope of the study is global. This report estimates market data for 2022 (the base year) and provides forecasts for 2023 through 2028. Figures for 2023 are estimated, except where actual results have been reported. This report includes forecasts by product type and region from 2023 through 2028. Genetic testing for inherited prostate cancer risk assessment is beyond the scope of the report. The Report Includes 31 data tables and 63 additional tables An overview of the global market for the technologies for prevention and treatment of prostate cancer Analysis of global market trends, featuring historical revenue data for 2020-2022, estimated figures for 2023, forecasts for 2024, and projections of compound annual growth rates (CAGRs) through 2028 Evaluation of the current market size and revenue growth prospects specific to prevention and treatment of prostate cancer, accompanied by a market share analysis by test type, treatment type, drug type and geographic region Description of several types of prostate cancer, namely acinar adenocarcinoma, ductal adenocarcinoma, transitional cell (or urothelial) cancer, small cell prostate cancer and carcinoid and sarcomas Description of biomarker tests such as the prostate-specific antigen (PSA) test, digital rectal exam (DRE) and prostate biopsy, and a discussion on their advantages and limitations Information on poly adenosine diphosphate-ribose polymerase (PARP) inhibitors, their limitations and approvals related to their use as targeted therapy for prostate cancer Coverage of approvals for metastatic castration resistant prostate cancer (mCRPC), and collaborations and licensing agreements for the treatment of prostate cancer Evaluation of the current and future market potential and an analysis of the regulatory framework and reimbursement scenarios Review of patents, product pipelines, ESG trends and emerging technologies related to prevention and treatment of prostate cancer Market share analysis of the key companies in the industry and coverage of mergers & acquisitions, joint ventures, collaborations, partnerships and other market strategies Profiles of leading market participants Key Topics Covered: Chapter 1 Introduction Chapter 2 Summary and Highlights Chapter 3 Market Overview Prostate Cancer Biology of Prostate Cancer Symptoms Screening Diagnosis Localized Prostate Cancer Metastatic Prostate Cancer Watchful Waiting or Active Surveillance Treatment Chapter 4 Market Dynamics Market Drivers Increasing Prevalence of Prostate Cancer Active Surveillance and Screening Personalized Care Approvals for Metastatic Castration-Resistant Prostate Cancer Collaborations and Licensing Agreements Market Challenges Loss of Exclusivity and Genericization Shortage of Care Providers and Other Resources Market Opportunities Chapter 5 Screening and Diagnosis Market by Test Type Biomarker Tests PSA Tests Limitations of PSA Tests Biomarker Tests for Early Prostate Cancer Detection in Elevated PSA Settings Digital Rectal Exam Limitations of DREs Prostate Biopsy Grade (Gleason Score) of Prostate Cancer Prostatic Intraepithelial Neoplasia Atypical Small Acinar Proliferation Proliferative Inflammatory Atrophy Intraductal Carcinoma of the Prostate Limitations of Prostate Biopsies Imaging Technologies for Prostate Cancer Market for Prostate Cancer Screening/Diagnosis, by Test Type Biomarker Tests DREs Prostate Biopsies Chapter 6 Pharmaceuticals Market by Drug Type Hormone Therapy Androgen Deprivation Therapy Antiandrogen Therapies Hormone Therapy Uses in Prostate Cancer Treatment Targeted Therapy PARP Inhibitors Radioligand Therapies Small Molecule Targeted Agents Monoclonal Antibodies Chemotherapy Immunotherapy Market Revenue, by Drug Type Hormone Therapy Targeted Therapy Immunotherapy Chemotherapy Chapter 7 Market for Surgery and Radiation Therapy by Treatment Type Active Surveillance Radical Prostatectomy Robotic Prostatectomy Open Radical Prostatectomy Laparoscopic Prostatectomy Radical Prostatectomy Market Revenue Radiation Therapy External Beam Radiation Therapy Brachytherapy Combined Radiation Therapy Radiation Therapy Device Market Revenue Chapter 8 Market Breakdown by Region Chapter 9 Emerging Technologies and Developments Liquid Biopsy Multiparametric MRI Homologous Recombination Repair Gene Mutation Advanced Radiotherapy Techniques AI and Machine Learning Chapter 10 Pipeline Analysis Chapter 11 Competitive Intelligence Screening and Diagnosis Market Market for Radiation Therapy Devices Pharmaceuticals Market Chapter 12 Company Profiles Abbott Accuray Astellas Pharma Astrazeneca Bayer Danaher Corp. Dendreon Pharmaceuticals Elekta F. Hoffmann-La Roche Johnson & Johnson Services Pfizer Sanofi Siemens Healthineers For more information about this report visit About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets